Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin B, Fragale G, Karl A, Losisolo P, Trimarchi H, Hoyos I, Lampo M, Monkowski M, De La Fuente J, Alvarez M, Stoppa D, Chiurchiu C, Novoa P, Orias M, Barron M, Giotto A, Arriola M, Cassini E, Maldonado R, Dionisi M, Ryan J, Toussaint N, Luxton G, Peh C, Levidiotis V, Francis R, Phoon R, Fedosiuk E, Toropilov D, Yakubtsevich R, Mikhailova E, Bovy C, Demoulin N, Hougardy J, Maes B, Speeckaert M, Laurin L, Barbour S, Masse M, Hladunewich M, Reich H, Cournoyer S, Tennankore K, Barbour S, Lv J, Liu Z, Wang C, Li S, Luo Q, Ni Z, Yan T, Fu P, Cheng H, Liu B, Lu W, Wang J, Chen Q, Wang D, Xiong Z, Chen M, Xu Y, Wei J, Pai P, Chen L, Rehorova J, Maixnerova D, Safranek R, Rychlik I, Hruby M, Makela S, Vaaraniemi K, Ortiz F, Alamartine E, Daroux M, Cartery C, Vrtovsnik F, Serre J, Stamellou E, Vielhauer V, Hugo C, Budde K, Otte B, Nitschke M, Ntounousi E, Boletis I, Papagianni A, Goumenos D, Stylianou K, Zermpala S, Esposito C, Cozzolino M, Viganò S, Gesualdo L, Nowicki M, Stompor T, Kurnatowska I, Kim S, Kim Y, Na K, Kim D, Kim S, Porras L, Garcia E, Pamplona I, Segarra A, Goicoechea M, Fellstrom B, Lundberg S, Hemmingsson P, Guron G, Sandell A, Chen C, Tokgoz B, Duman S, Altiparmak M, Ergul M, Maxwell P, Mark P, McCafferty K, Khwaja A, Cheung C, Hall M, Power A, Kanigicherla D, Baker R, Moriarty J, Mohamed A, Aiello J, Canetta P, Ayoub I, Robinson D, Thakar S, Mottl A, Sachmechi I, Fischbach B, Singh H, Mulhern J, Kamal F, Linfert D, Rizk D, Wadhwani S, Sarav M, Campbell K, Coppock G, Luciano R, Sedor J, Avasare R, Lau W. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International 2022, 103: 391-402. PMID: 36270561, DOI: 10.1016/j.kint.2022.09.017.Peer-Reviewed Original Research